Retraction notice to "UHRF2, another E3 ubiquitin ligase for p53" [Biochem. Biophys. Res. Commun. 425 (2012) 908-911];UHRF2, another E3 ubiquitin ligase for p53

Biochemical and Biophysical Research Communications

Volumn 425, Issue 4, 2012, Pages 908-911

  Bai, Lu ^a   Wang, Xiaohui ^a   Jin, Fangmin ^a   Yang, Yan ^a   Qian, Guanhua ^a   Duan, Changzhu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Epigenetics; P53; Ubiquitin ligase; UHRF2

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DNA METHYLTRANSFERASE; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; UHRF2 ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE REGULATION; DNA METHYLATION; EPIGENETICS; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN INTERACTION; UBIQUITINATION;

EID: 84865986381     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.009     Document Type: Erratum

References (24)

1. Brady C.A., Attardi L.D. p53 at a glance. J Cell Sci. 2010, 123:2527-2532.
2. Aylon Y., Oren M. New plays in the p53 theater. Curr. Opin. Genet. Dev. 2011, 21:86-92.
3. Brooks C.L., Gu W. New insights into p53 activation. Cell Res. 2010, 20:614-621.
4. Das S.K., Hashimoto T., Shimizu K., Yoshida T., Sakai T., Sowa Y., Komoto A., Kanazawa K. Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim. Biophys. Acta 2005, 1726:328-335.
5. Korenjak M., Brehm A. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr. Opin. Genet. Dev. 2005, 15:520-527.
6. Münger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 2002, 89:213-228.
7. Bartkova J., Grøn B., Dabelsteen E., Bartek J. Cell-cycle regulatory proteins in human wound healing. Arch. Oral Biol. 2003, 48:125-132.
8. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997, 11:2090-2100.
9. Mori T., Li Y., Hata H., Ono K., Kochi H. NIRF, a novel RING finger protein, is involved in cell-cycle regulation. Biochem. Biophys. Res. Commun. 2002, 296:530-536.
10. Bronner C., Achour M., Arima Y., Chataigneau T., Saya H., Schini-Kerth V.B. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future. Pharmacol. Ther. 2007, 115:419-434.
11. Li Y., Mori T., Hata H., Homma Y., Kochi H. NIRF induces G1 arrest and associates with Cdk2. Biochem. Biophys. Res. Commun. 2004, 319:464-468.
12. Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H. NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle 2011, 10:3284-3299.
13. Mori T., Li Y., Hata H., Kochi H. NIRF is a ubiquitin ligase that is capable of ubiquitinating PCNP, a PEST-containing nuclear protein. FEBS Lett. 2004, 557:209-214.
14. Hock A., Vousden K.H. Regulation of the p53 pathway by ubiquitin and related proteins. Int. J. Biochem. Cell Biol. 2010, 42:1618-1621.
15. Lee J.T., Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17:86-92.
16. Allende-Vega N., Saville M.K. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Semin. Cancer Biol. 2010, 20:29-39.
17. Marine J.C., Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010, 17:93-102.
18. Brooks C.L., Gu W. p53 regulation by ubiquitin. FEBS Lett. 2011, 585:2803-2809.
19. Tsvetkov P., Reuven N., Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ. 2010, 17:103-108.
20. Unoki M., Nishidate T., Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004, 23:7601-7610.
21. Pichler G., Wolf P., Schmidt C.S., Meilinger D., Schneider K., Frauer C., Fellinger K., Rottach A., Leonhardt H. Cooperative DNA and histone binding by Uhrf2 links the two major repressive epigenetic pathways. J. Cell Biochem. 2011, 112:2585-2593.
22. Iwata A., Nagashima Y., Matsumoto L., Suzuki T., Yamanaka T., Date H., Deoka K., Nukina N., Tsuji S. Intranuclear degradation of polyglutamine aggregates by the ubiquitin-proteasome system. J. Biol. Chem. 2009, 284:9796-9803.
23. Mori T., Ikeda D.D., Yamaguchi Y., Unoki M. NIRF/UHRF2 occupies a central position in the cell cycle network and allows coupling with the epigenetic landscape. FEBS Lett. 2012, 586:1570-1583.
24. Zhang J., Gao Q., Li P., Liu X., Jia Y., Wu W., Li J., Dong S., Koseki H., Wong J. S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance. Cell Res. 2011, 21:1723-1739.